Americas GERD & NERD Treatment Market Research Report- Forecast till 2027

Americas Gerd & Nerd Treatment Market Information, By Drug Class (Antacids (Acid Neutralizers), Proton Pump Inhibitors, H2 Receptor Blocker), Dosage Form (Solid And Liquid), End User (Hospitals & Clinics, Research Centers, And Others) -Forecast Till 2027

ID: MRFR/Pharma/4106-CR | February 2018 | Region: Global | 90 Pages         

1 Report Prologue

2 Market Introduction

2.1 Definition 14

2.2 Scope of the Study 14

2.2.1 Research Objective 14

2.2.2 Assumptions 14

2.2.3 Limitations 14

3 Research Methodology

3.1.1 Primary Research Methodology 17

3.1.2 Data Points Received from the Doctors/ Gastrologist: 17

3.1.3 Data points received from the Manufacturer/ Pharmaceutical Companies: 18

3.1.4 Data points received from Hospitals, Clinics: 18

3.1.5 Secondary Research Methodology 20

3.1.6 Market Share Analysis 22

3.1.7 Trade Analysis 22

3.1.8 Market Pricing Approach 22

4 Market Dynamics

4.1 Introduction 23

4.2 Drivers 24

4.2.1 Increasing cases of smoking to boost the market growth (Impact weightage- 20%) 24

4.2.2 Rising cases of reflux disorder during pregnancy (impact weightage- 15%) 25

4.2.3 Changing lifestyle and irregular dietary habits (Impact weightage- 15%) 26

4.2.4 Increasing incidence of acid reflux disorder (heartburn) will boost the American GERD& NERD treatment market (Impact weightage- 25%) 27

4.2.5 Growing geriatric population (impact weightage- 15%) 28

4.2.6 Increasing demands for endoscopy biopsy procedures for early diagnosis (Impact weightage- 10%) 29

4.3 Restraints 30

4.3.1 Loss of patent exclusivity and lack of pipeline drugs (impact weightage- 55%) 30

4.3.2 High cost of the gastroscopes (weightage impact- 45%) 31

4.4 Opportunity 32

4.4.1 Development of new drugs 32

4.5 Mega Trends 32

4.6 Macroeconomic Indicators 32

4.7 Technology Trends & Assessment 33

5 Market Factor Analysis

5.1 Porters Five forces Model 34

5.1.1 Bargaining Power of Suppliers 35

5.1.2 Bargaining Power of Buyers 35

5.1.3 Threat of New Entrants 35

5.1.4 Threat of Substitutes 35

5.1.5 Intensity of Rivalry 36

5.2 Value Chain Analysis 36

5.2.1 R&D 37

5.2.2 Manufacturing 37

5.2.3 Distribution & Sales 37

5.2.4 Post-Sales Monitoring 37

5.3 Demand & Supply: Gap Analysis 38

5.4 Pricing Analysis 38

5.5 Investment Opportunity Analysis 38

6 Americas GERD & NERD Treatment Market, by Drug class

6.1 Introduction 39

6.2 Antacids (Acid Neutralizers) 40

6.3 Proton Pump Inhibitors 41

6.3.1 Esomeprazole 41

6.3.2 Omeprazole 42

6.3.3 Pantoprazole 42

6.3.4 Lansoprazole 43

6.3.5 Dexlansoprazole 43

6.3.6 Rabeprazole 43

6.4 H2 receptor blocker 44

6.4.1 Ranitidine 44

6.4.2 Famotidine 45

6.4.3 Cimetidine 45

6.4.4 Nizatidine 46

6.5 Pro kinetic agents 46

6.5.1 Domperidone 46

6.5.2 Metoclopramide 47

6.5.3 Itopride 47

6.5.4 Prucalopride 47

6.5.5 Cisapride 48

6.5.6 Benzamide 48

6.5.7 Mosapride 48

6.5.8 Erythromycin 49

6.6 Antidepressants 49

6.7 Calcium Channel Blockers 50

7 Americas GERD & NERD Treatment Market, by Dosage Form

7.1 Introduction 51

7.2 Solid 52

7.3 Liquid 52

8 Americas GERD & NERD Treatment Market, by End User

8.1 Introduction 53

8.2 Hospitals & Clinics 54

8.3 Research Centers 54

9 Americas GERD & NERD Treatment Market, by Region

9.1 Introduction 55

9.2 North America 57

9.2.1 U.S. 60

9.2.2 Canada 63

9.3 South America 66

10 Competitive Landscape

10.1 Introduction 69

10.2 Company Share Analysis 69

11 Company Profiles

11.1 AstraZeneca 70

11.1.1 Company Overview 70

11.1.2 Financials 70

11.1.3 Products 70

11.1.4 Strategy 70

11.1.5 Key Developments 70

11.2 Addex Pharmaceuticals 71

11.2.1 Company Overview 71

11.2.2 Financials 71

11.2.3 Products 71

11.2.4 Strategy 71

11.2.5 Key Developments 71

11.3 Takeda Pharmaceutical 72

11.3.1 Company Overview 72

11.3.2 Financials 72

11.3.3 Products 72

11.3.4 Strategy 72

11.3.5 Key Developments 72

11.4 Eisai Co., Ltd 73

11.4.1 Company Overview 73

11.4.2 Financials 73

11.4.3 Products 73

11.4.4 Strategy 73

11.4.5 Key Developments 73

11.5 Medigus Ltd 74

11.5.1 Company Overview 74

11.5.2 Financials 74

11.5.3 Products 74

11.5.4 Strategy 74

11.5.5 Key Developments 74

11.6 RaQualia Pharma Inc 75

11.6.1 Company Overview 75

11.6.2 Financials 75

11.6.3 Products 75

11.6.4 Strategy 75

11.6.5 Key Developments 75

11.7 Torax Medical 76

11.7.1 Company Overview 76

11.7.2 Financials 76

11.7.3 Products 76

11.7.4 Strategy 76

11.7.5 Key Developments 76

11.8 Carbon Medical technologies 77

11.8.1 Company Overview 77

11.8.2 Financials 77

11.8.3 Products 77

11.8.4 Strategy 77

11.8.5 Key Developments 77

11.9 Endogastric Solutions 78

11.9.1 Company Overview 78

11.9.2 Financials 78

11.9.3 Products 78

11.9.4 Strategy 78

11.9.5 Key Developments 78

11.10 Medtronic 79

11.10.1 Company Overview 79

11.10.2 Financials 79

11.10.3 Products 79

11.10.4 Strategy 79

11.10.5 Key Developments 79

11.11 Pfizer 80

11.11.1 Company Overview 80

11.11.2 Financials 80

11.11.3 Products 80

11.11.4 Strategy 80

11.11.5 Key Developments 80

11.12 Novartis AG. 81

11.12.1 Company Overview 81

11.12.2 Financials 81

11.12.3 Products 81

11.12.4 Strategy 81

11.12.5 Key Developments 81

11.13 GlaxoSmithKline plc 82

11.13.1 Company Overview 82

11.13.2 Financials 82

11.13.3 Products 82

11.13.4 Strategy 82

11.13.5 Key Developments 82

11.14 Valeant Pharmaceuticals 83

11.14.1 Company Overview 83

11.14.2 Financials 83

11.14.3 Products 83

11.14.4 Strategy 83

11.14.5 Key Developments 83

11.15 Ironwood Pharmaceuticals, Inc. 84

11.15.1 Company Overview 84

11.15.2 Financials 84

11.15.3 Products 84

11.15.4 Strategy 84

11.15.5 Key Developments 84

12 Appendix

12.1 Discussion Blue Print 85

13 MRFR Conclusion

13.1 Key Findings 87

13.1.1 From CEO’s View Point 87

13.1.2 Unmet Needs 87

13.2 Key companies to watch 87

14 List of Tables

TABLE 1 PRIMARY INTERVIEWS 19

TABLE 2 AMERICAS GERD & NERD TREATMENT MARKET, BY ANTACIDS (ACID NEUTRALIZERS), 2020 & 2027 (USD MILLION) 40

TABLE 3 AMERICAS GERD & NERD TREATMENT MARKET, BY PROTON PUMP INHIBITORS, 2020 TO 2027 (USD MILLION) 41

TABLE 4 AMERICAS GERD & NERD TREATMENT MARKET, BY ESOMEPRAZOLE, 2020 TO 2027 (USD MILLION) 41

TABLE 5 AMERICAS GERD & NERD TREATMENT MARKET, BY OMEPRAZOLE, 2020 TO 2027 (USD MILLION) 42

TABLE 6 AMERICAS GERD & NERD TREATMENT MARKET, BY PANTOPRAZOLE, 2020 TO 2027 (USD MILLION) 42

TABLE 7 AMERICAS GERD & NERD TREATMENT MARKET, BY LANSOPRAZOLE, 2020 TO 2027 (USD MILLION) 43

TABLE 8 AMERICAS GERD & NERD TREATMENT MARKET, BY DEXLANSOPRAZOLE, 2020 TO 2027 (USD MILLION) 43

TABLE 9 AMERICAS GERD & NERD TREATMENT MARKET, BY RABEPRAZOLE, 2020 TO 2027 (USD MILLION) 43

TABLE 10 AMERICAS GERD & NERD TREATMENT MARKET, BY H2 RECEPTOR BLOCKER, 2020 TO 2027 (USD MILLION) 44

TABLE 11 AMERICAS GERD & NERD TREATMENT MARKET, BY RANITIDINE, 2020 TO 2027 (USD MILLION) 44

TABLE 12 AMERICAS GERD & NERD TREATMENT MARKET, BY FAMOTIDINE, 2020 TO 2027 (USD MILLION) 45

TABLE 13 AMERICAS GERD& NERD TREATMENT MARKET, BY CIMETIDINE, 2020 TO 2027 (USD MILLION) 45

TABLE 14 AMERICAS GERD & NERD TREATMENT MARKET, BY NIZATIDINE, 2020 TO 2027 (USD MILLION) 46

TABLE 15 AMERICAS GERD & NERD TREATMENT MARKET, BY DOMPERIDONE, 2020 TO 2027 (USD MILLION) 46

TABLE 16 AMERICAS GERD & NERD TREATMENT MARKET, BY METOCLOPRAMIDE, 2020 TO 2027 (USD MILLION) 47

TABLE 17 AMERICAS GERD & NERD TREATMENT MARKET, BY ITOPRIDE, 2020 TO 2027 (USD MILLION) 47

TABLE 18 AMERICAS GERD & NERD TREATMENT MARKET, BY PRUCALOPRIDE, 2020 TO 2027 (USD MILLION) 47

TABLE 19 AMERICAS GERD & NERD TREATMENT MARKET, BY CISAPRIDE, 2020 TO 2027 (USD MILLION) 48

TABLE 20 AMERICAS GERD & NERD TREATMENT MARKET, BY BENZAMIDE, 2020 TO 2027 (USD MILLION) 48

TABLE 21 AMERICAS GERD & NERD TREATMENT MARKET, BY MOSAPRIDE, 2020 TO 2027 (USD MILLION) 48

TABLE 22 AMERICAS GERD & NERD TREATMENT MARKET, BY ERYTHROMYCIN, 2020 TO 2027 (USD MILLION) 49

TABLE 23 AMERICAS GERD & NERD TREATMENT MARKET, BY ANTIDEPRESSANTS, 2020 TO 2027 (USD MILLION) 49

TABLE 24 AMERICAS GERD & NERD TREATMENT MARKET, BY CALCIUM CHANNEL BLOCKERS, 2020 TO 2027 (USD MILLION) 50

TABLE 25 AMERICAS GERD & NERD TREATMENT MARKET, BY SOLID, 2020 TO 2027 (USD MILLION) 52

TABLE 26 AMERICAS GERD & NERD TREATMENT MARKET, BY LIQUID, 2020 TO 2027 (USD MILLION) 52

TABLE 27 AMERICAS GERD & NERD TREATMENT MARKET, BY HOSPITALS & CLINICS, 2020 TO 2027 (USD MILLION) 54

TABLE 28 AMERICAS GERD & NERD TREATMENT MARKET, BY RESEARCH CENTERS, 2020 TO 2027 (USD MILLION) 54

TABLE 29 AMERICAS GERD & NERD TREATMENT MARKET, BY REGION, 2020 TO 2027 (USD MILLION) 56

TABLE 30 NORTH AMERICA GERD & NERD TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 57

TABLE 31 NORTH AMERICA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 57

TABLE 32 NORTH AMERICA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 58

TABLE 33 NORTH AMERICA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 58

TABLE 34 NORTH AMERICA GERD & NERD TREATMENT MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION) 59

TABLE 35 NORTH AMERICA GERD & NERD TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 59

TABLE 36 U.S. GERD & NERD TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 60

TABLE 37 U.S. GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 60

TABLE 38 U.S. GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 61

TABLE 39 U.S. GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 61

TABLE 40 U.S. GERD & NERD TREATMENT MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION) 62

TABLE 41 U.S. GERD & NERD TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 62

TABLE 42 CANADA GERD & NERD TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 63

TABLE 43 CANADA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 63

TABLE 44 CANADA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 64

TABLE 45 CANADA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 64

TABLE 46 CANADA GERD & NERD TREATMENT MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION) 65

TABLE 47 CANADA GERD & NERD TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 65

TABLE 48 SOUTH AMERICA GERD & NERD TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 66

TABLE 49 SOUTH AMERICA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 66

TABLE 50 SOUTH AMERICA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 67

TABLE 51 SOUTH AMERICA GERD & NERD TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 67

TABLE 52 SOUTH AMERICA GERD & NERD TREATMENT MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION) 68

TABLE 53 SOUTH AMERICA GERD & NERD TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 68

15 List of Figures

FIGURE 1 AMERICAS GERD & NERD TREATMENT MARKET, BY DRUG CLASS, 2020 & 2027 (USD MILLION) 12

FIGURE 2 AMERICAS GERD & NERD TREATMENT MARKET, BY DOSAGE FORM, 2020 & 2027 (USD MILLION) 12

FIGURE 3 AMERICAS GERD & NERD TREATMENT MARKET, BY END USER, 2020 & 2027 (USD MILLION) 13

FIGURE 4 MARKET STRUCTURE 15

FIGURE 5 RESEARCH METHODOLOGY 16

FIGURE 6 DATA TRIANGULATION PRIMARY 19

FIGURE 7 DATA TRIANGULATION METHOD 21

FIGURE 8 PORTER’S FIVE FORCES MODEL 34

FIGURE 9 AMERICAS GERD & NERD TREATMENT MARKET, BY DRUG CLASS, 2020 & 2027 (USD MILLION) 39

FIGURE 10 AMERICAS GERD & NERD TREATMENT MARKET, BY DOSAGE FORM, 2020 & 2027 (USD MILLION) 51

FIGURE 11 AMERICAS GERD & NERD TREATMENT MARKET, BY END USER, 2020 & 2027 (USD MILLION) 53

FIGURE 12 AMERICAS GERD & NERD TREATMENT MARKET, BY END USER, 2020 & 2027 (USD MILLION) 56

GERD and NERD Treatment Market Speak to Analyst Request a Free Sample

Americas GERD & NERD Treatment Market


Over the last two hundred years, acid reflux has been a common lifestyle problem and also experienced a few setbacks in the U.S. Though, the ultimate goal of the gastroesophageal reflux treatment has always remained the same, which is to suppress the symptoms of the GERD patient. GERD affects up to 40% of the U.S. population in their lifetime and is a part of an increasingly significant public health burden. When GERD is not properly managed, it can lead to Barrett's esophagus. The lifetime risk of progression from GERD to Barrett's esophagus is 26.5%. Early diagnosis and treatment of Barrett's esophagus are crucial because it is the primary risk factor for esophageal cancer. The incidence of acid reflux disorder, also known as heartburn, is rapidly increasing worldwide. Various studies state that almost every person experiences acid reflux once in a lifetime. GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives but also extends to the healthcare system and economy.


The major driving factors for growth of the Americas GERD & NERD treatment market are increasing cases of smoking, rising cases of reflux disorder during pregnancy, changing lifestyle, and irregular dietary habits. Moreover, increasing incidence of acid reflux disorder (heartburn), growing geriatric population are likely to fuel the market growth during the forecast period.    


The Americas GERD & NERD treatment market is expected to grow at the CAGR of 4.02% during the forecast period 2017-2023


Figure- Americas GERD & NERD treatment market, by End User 2016 (%)


 America GERD & NERD treatment market


Source: Source: World Health Organisation, Ministry of Health U.S, Department of Pharmaceutical, National Institute on Drug abuse, American Gastroenterological Association, American College of Gastroenterology, Pediatric/Adolescent Gastroesophageal Reflux Associatestinal Society Anxiety and Depression Association of America, and white papers published by various government organizations, MRFR Analysis


Intended Audience:



  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology:
America GERD & NERD treatment market 1


Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis


Segmentation


The Americas GERD & NERD treatment market is segmented on the basis of drug class, dosage form, and by the end user.


On the basis of the drug class, the Americas GERD & NERD treatment market is segmented into antacids (acid neutralizers), proton pump inhibitors, H2 receptor blocker, prokinetic agents, antidepressants, calcium channel blockers, and others. Proton pump inhibitors are further segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. H2 receptor blocker is further segmented into ranitidine, famotidine, cimetidine, nizatidine, and others. Prokinetic agents are further segmented into domperidone, metoclopramide, itopride, prucalopride, cisapride, benzamide, mosapride, erythromycin, and others.


Based on the dosage form, Americas GERD & NERD treatment market is segmented into solid and liquid.


On the basis of the end user, Americas GERD & NERD treatment market is segmented into hospitals & clinics, research centers, and others.


Regional Analysis


The Americas GERD & NERD treatment market is growing at a steady pace. North America contributed the largest share to the GERD & NERD treatment market owing to continuously increasing demand for the medical devices, increasing number of healthcare organization, and the presence of huge patient population. Increasing cases of smoking are projected to fuel in the Americas market. The South American region accounts the least share of the market.


Key Findings:



  • Antacids segment dominates the market with nearly 26.11% share of the Americas GERD & NERD treatment market

  • Americas GERD & NERD treatment market was estimated to be USD 2,350.37 million in 2016

  • Proton pump inhibitors segment is expected to be the second largest market, which is expected to reach USD 773.62 million by 2023


Key Players in the Americas GERD & NERD Treatment Market


Some of the major players in Americas GERD & NERD treatment are: AstraZeneca Plc (U.K), Boston Scientific Corporation (U.S.), Cempra Inc. (U.S.), Eisai Co., Ltd. (Japan), EndoGastric Solutions Inc. (U.S.), EndoStim Inc. (U.S.), GlaxoSmithKline Plc (U.K), Ironwood Pharmaceuticals, Inc. (U.S.), Jeil pharmaceutical Co. Ltd. (South Korea), Johnson & Johnson (U.S.), Mederi Therapeutics Inc. (U.S.), Medigus Ltd. (Israel), Medtronic Inc. (U.S.), Merck & CO., Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceuticals Industries Limited (Israel), Torax Medical (U.S.), Valeant Pharmaceuticals International, Inc. (Canada), Carbon Medical technologies (U.S.), Allegiant health (U.S.), Tya pharmaceuticals (U.S.), and Sanofi (France).



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Americas GERD & NERD treatment market is projected to grow at a 4.02% CAGR By 2023

The Americas is expected to dominate the GERD & NERD treatment market.

Rising incidence of reflux disorder and increasing cases of smoking are key factors driving the GERD & NERD treatment market.

Proton pump inhibitors will dominate the GERD & NERD treatment market.

End users of the GERD & NERD treatment market include research centers, hospitals and clinics, and others.